display

Tübingen (dpa) - The chemical company Wacker wants to start contract production of the corona vaccine for the Tübingen biotech company Curevac this spring.

The approval by the EU drug authority EMA is expected by the beginning of May, said the designated Wacker CEO Christian Hartel on Tuesday in Munich.

Production is then to be increased to the full capacity of 100 million vaccine doses per year by July.

The Munich company has the vaccine manufactured in Amsterdam.

According to Hartel, it would also be possible to double production to 200 million cans per year.

Maximum capacity in three to four years with additional production in the Saxon plant in Nünchritz would be almost 400 million cans.

"We also have ongoing discussions with Biontech and Moderna, but there is nothing to report at the moment," said Hartel.

Curevac has made contract manufacturing agreements with several industrial companies, including Bayer and Novartis.

The EMA started the rapid testing process for the Curevac vaccine in February.

display

© dpa-infocom, dpa: 210316-99-843776 / 2